Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Oct. 27, 2024	Oct. 29, 2023
Cash flows from operating activities:
Net loss	$ (201,040,000)	$ (449,672,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	33,211,000	69,104,000
Amortization of right-of-use assets	4,542,000	4,954,000
Investment impairments and credit loss reserves, net	1,109,000	2,250,000
Goodwill impairment	0	281,821,000
Accretion of deferred financing costs	6,814,000	4,940,000
Write-off of deferred financing costs	5,497,000	4,446,000
Loss on extinguishment of debt	143,467,000	0
Deferred income taxes	(944,000)	56,355,000
Share-based compensation	50,777,000	28,341,000
Loss (gain) on disposition of business operations and assets	124,000	(259,000)
Equity method (income) loss	(38,000)	30,000
Gain from sale of investments	(277,000)	0
Corporate-owned life insurance, net	2,722,000	2,797,000
Amortization of inventory step-up	0	3,314,000
Changes in assets and liabilities:
Accounts receivable, net	(8,142,000)	5,016,000
Inventories	(18,446,000)	41,631,000
Other assets	597,000	(13,203,000)
Accounts payable	18,911,000	(33,768,000)
Accrued liabilities	(8,813,000)	(109,127,000)
Other liabilities	(5,580,000)	(6,809,000)
Net cash provided by (used in) operating activities	24,491,000	(107,839,000)
Cash flows from investing activities:
Proceeds from sales of property, plant and equipment	73,000	408,000
Purchase of property, plant and equipment	(5,228,000)	(27,473,000)
Proceeds from sale of investments	2,650,000	0
Purchase of investments	(434,000)	(930,000)
Purchase of intangibles	(5,948,000)	(771,000)
Proceeds from corporate-owned life insurance	4,802,000	2,500,000
Net cash used in investing activities	(4,085,000)	(26,266,000)
Cash flows from financing activities:
Proceeds from revolving line of credit	0	70,000,000
Payments of revolving line of credit	(5,000,000)	0
Payments of term loans	0	(272,375,000)
Proceeds from convertible senior notes	0	250,000,000
Deferred financing costs	(824,000)	(17,812,000)
Payments for employee share-based compensation payroll taxes	(7,297,000)	(5,476,000)
Proceeds from exercise of stock options	1,248,000	0
Distributions to noncontrolling interest	(184,000)	0
Net cash (used in) provided by financing activities	(12,057,000)	24,337,000
Effect of foreign exchange rate changes on cash and cash equivalents	(430,000)	(1,922,000)
Net increase (decrease) in cash and cash equivalents	7,919,000	(111,690,000)
Cash and cash equivalents at beginning of period	128,585,000	235,510,000
Cash and cash equivalents at end of period	136,504,000	123,820,000
Supplemental disclosure of cash flow information:
Interest paid	60,563,000	63,525,000
Income taxes paid	6,881,000	19,655,000
Non-cash investing and financing activities:
Accounts payable related to capital expenditures	511,000	281,000
Accrued deferred financing costs	0	8,418,000
Accrued purchases of intangibles	2,950,000	0
Debt extinguished in exchange for common stock	188,050,000	0
Conversion of notes into equity	$ 0	$ 1,271,000